(C) Private 2009 - Martin Schroeder, Accovion GmbHMartin Schröder appointed CEO of Accovion,
Co-founder Wilhelm Horn quits

July 2009. Accovion GmbH is a CRO specialised in biostatistics services provider for clinical trials, reimbursement documentation and management of drugs.

January 2014. Martin Schröder, who founded the company as spin-off from Aventis (today: Sanofi) in 2001 retired at age 62 in January 2014. Andree Beckerling (44), a medical doctor formerly working for Pierrel S.p.A. at IFE Europe, Bochum (today THERAMetrics GmbH) succeeded Mr. Schröder. Updated January 2014

If you like to read this article, you can purchase it now

Please notice, when purchasing articles you agree to B2Bioworld's Terms and Conditions

Read Now - Please select your license (Prices incl. 7% VAT)

Article free of advertisement - 1 page

Full Company License enquire here

Back to section

Related Editorial Articles

Clinipace Pays High Sum for Accovion
Includes figures of the transaction

Make or Break Drug Discovery and Biopharma of Merck Life Science

Transition: Cancer Research Translation
Christof von Kalle, Head of Germany’s National Center for Tumor Diseases on transitions in translational cancer research

Patient-centered Precision Care
Michael Christman, President of Coriell Institute about turning research on human genotyping into healthcare routine

The Myriad Way
Peter D Meldrum, at the time CEO of the genetics company about battles on patents, cancer chips, and competitors in commercial academia

Custom Sequencing Markets
Worldwide evolution of the market and upcoming business opportunities

Metrics for Disease, Health, and Wellness
A systems look at DNA sequencing for personalized medicine by Leroy Hood, President Institute for Systems Biology, Seattle

Network intelligence for Lundbeck’s new drugs